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NICU : Neonatal Intensive Care Unit 
ABO : blood groups 
CBB : cord blood bilirubin
NNH : neo-natal hyperbilirubinemia
HDN : hemolytic disease of newborn
Rh : rhesus
RBC : red blood cell
CBC : complete blood count
MCV : mean corpuscular volume
HB : hemoglobin
PCV : packed cell volume
mg /dl : milligram per decilitre
Kg : kilogram
µmol/L : micro moles per litre
sq.cm/nm : square centimeter per nanometre
NADPH : nicotinamide adenine dinucleotide phosphate hydrogen
O2 : oxygen 
CO : carbon monoxide
Fe : iron chemical symbol
AAP : American academy of paediatrics
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BBB : blood brain barrier
FFA : free fatty acid
CSF : cerebro spinal fluid
G6PD : glucose-6 phospate dehydrogenase
DCT : direct coomb’stest
BIND : bilirubin induced neurological delay
HPE : histo pathological examination
CNS : central nervous system
EDTA : ethylene diamine tetraacetic acid
TP : true positive
TN ; true negative
FP : false positive
FN : false negative
NPV : negative predictive value
PPV : positive predictive value
ROC : receiver operating curve
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Neonatal hyperbilirubinemia is a common problem which has to be treated irrespective 
of physiological / pathological etiology. As the liver matures, physiological neonatal 
hyperbilirubinemia resolves even if untreated , whereas in hemolytic states bilirubin reaches 
toxic levels causing irreversible brain damage (kernicterus). In a government institution like 
ours, due to inpatient overload, early discharge of neonates is common. Also common is that 
many of these early discharged neonates are readmitted with neonatal hyperbilirubinemia 
requiring phototherapy. This scenario in our NICU exerts extra load & financial strain to the
hospital , patients & treating staff, not to mention the emotional aspects of parents. After much 
brain storming, we decide to undertake this study through which we wanted to know whether 
bilirubin levels at birth in cord blood of ABO incompatibile babies could be a good predictor of 
severity of neonatal hyperbilirubinemia, thereby facilitating or reducing early discharge of these 
ABO incompatible neonates. Through this study , we also want to establish cut off values of 
cord blood bilirubin for prediction and management of these neonates with hyperbilirubinemia.





Aim of the study: 
 To establish a strong correlation between Cord blood bilirubin & neonatal 
hyperbilirubinemia in ABO incompatibility.
 To determine cut off values of Cord blood bilirubin & 24hrs bilirubin levels as 
predictors of neonatal hyperbilirubinemia in ABO incompatibility
 Early detection of neonatal hyperbilirubinemia to prevent the debilitating complications 
like kernicterus.





Neonatal Hyperbilirubinemia (NNH) is defined as the total serum bilirubin >5mg/dl. It 
is a commonly encountered problem.  These may  be as varied as physiological and pathological 
based on etiology.  The incidence of clinical jaundice in the first week of life is found to be 
60%.  Among these  jaundiced neonates , few have pathological etiology such as hemolytic 
disease of newborn (HDN), infections, metabolic disorders, endocrine abnormalities and 
congenital hepatic disorders. 
Clinically jaundice is the manifestation of unconjugated bilirubin deposit in skin and 
mucous membrane. Kramer et al has laid down guidelines for diagnosis of these bilirubin 
deposits in the skin based on the colour. 
These pathological cases are defined as those cases of hyperbilirubinemia which
requires treatment. They may be  conjugated or direct hyperbilirubinemia or indirect or 
unconjugated hyperbilirubinemia.  The following are the enumerated causes of neonatal 
Hyperbilirubinemia.
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                             FIG : 1 CAUSES OF NEONATAL HYPERBILIRUBINEMIA
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Risk factors for neonatal hyperbilirubinemia:
Maternal factors:




5. Drugs- oxytocin, diazepam 
Neonatal factors:






7. Previous affected sibling
Pathophysiology of Jaundice:-
In the human circulation, senescent RBC’s are broken down in the spleen resulting in 
degraded product producing heme.  This heme is phagocytosed by mononuclear cells and with 
the help of microsomal enzyme, heme oxygenase converted to biliverdin. Carbon monoxide , 
released in this reaction, is exhaled through lungs.
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One mole of hemoglobin produces one mole each of bilirubin & Carbon monoxide which inturn 
is reduced by bilirubin reductase & converted to bilirubin. 75% of this bilirubin is released from 
senescent RBC  in the reticuloenothelial system.
1g of HB produces 34mg(600µmol) bilirubin.in this degradation.
Accelerated release of Hb from RBC is the cause of hyperbilirubenemia in isoimmunisation ( 
Rh, ABO incompatibility),
25% of bilirubin is called early labeled bilirubin derived from Hb released by ineffective 
erythropoietin in the bone marrow, further heme containing protein in tissues ( eg. Myoglobin, 
cytokines, catalase, peroxidase) and frEee from heme.
At physiological pH, the insoluble bilirubin binds itself to albumin for transportation in 
the circulation.
This splenic circulation is brought to the liver, where hepatic conjugation with 
glucuronic acid (GLUCURONIDATION) occurs and bile is produced.  This is secreted in the 
intersitium and executed via the biliary cannaliculi subsequently into bile duct.
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FIG  : 2  BILIRUBIN FORMATION
27
                  
FIG : 3 HEME METABOLISM
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FIG : 4 CIRCULATION OF BILIRUBIN
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The bile secreted via bile ducts into second part of duodenum is converted in the colon 
by bacterial proteases into urobilinogen and stercobilinogen which is metabolized into Urobilin 
and Stercobilin which adds characteristic colour to the urine and fecaes respectively. 
                               
FIG : 5 CONJUGATION OF BILIRUBIN
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10% urobilinogen reabsorbed into circulation, adding colour to urine.  The rest of 90% 
urobilinogen is converted to stercobilin.
In the new born, there is relative polycythemia with shorter RBC life span (80 days in 
new born and 120 days in adults).  This results in increased RBC turnover in the new born, 
thereby producing double amount of bilirubin compared to adults.  Hence serum bilirubin levels 
are increased in newborn in later life.  Increased enterohepatic circulation, immature hepatic 
update and conjugation also contributes.  This combination of factors results in a normal 
physiological  hyperbilirubinemia common in newborn.  This is quite harmless and manageable.
Physiological Jaundice:-
Physiological Jaundice is due to immature hematological systems appears between 1 – 3 
days.  Reaches its peak 5 – 6 mg/dl (86-103 µmol/L) by 3 - 4th day and regresses by 14th day of 
life.  It occurs due to unconjugated hyperbilirubinemia and usually bilirubin is <15mg/dl.  It is 
more seen in artificial feeding.  In term healthy neonates without hemolysis , upto 17 mg/dl
(291µmol/L) bilirubin levels are termed as normal (as per AAP recommendation). Whereas in 
preterm neonates safe level vary based on gestational age.  Healthy term baby is the born at
term in absence of any hemolysis or significant illness. When total serum bilirubin level is 
<4mg/dl , clinically there is no icterus.
Breast Feeding Jaundice:
Compared to artificially fed babies, breastfed babies follow a different jaundice 
progression.  In breastfed neonates, jaundice appears at 1 – 3 days and peaks by two weeks of 
life, regresses by 3rd week of life.  Comparatively they tend to have higher bilirubin levels.  This 
pattern is not due to breast milk person but because of frequency of breast feeds.  Reduced 
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frequency is associated with increased physiological jaundice.  Hence 10 – 12 feeds/day is 
recommended in a term healthy baby.
Breast milk Jaundice:-
Breast milk jaundice is diagnosed wherever unconjugated hyperbilirubinemia occurs in a 
good vigorous healthy feeding baby who is gaining weight adequately and all other causes of 
hyperbilirubinemia have been excluded.  These infants have higher bilirubin due to Beta -
glucuronidase in breast milk.  They also have lesser intestinal bacteria, therefore, excrete less in 
stool.
Pathological Jaundice:-
Hyperbilirubinemia which requires intervention is defined as pathological jaundice
                              > appears of jaundice within 24 hours
> with per day increase of serum bilirubin > 5mg/dl/day
> peak level well above the expected range
> continuation of clinical jaundice > two weeks with conjugated 
bilirubin (> 14 days in problem and 8 days in term neonates)




- Other minor blood group incompatibility
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Rh Incompatibility:-
Babies born to a Rh positive father and Rh negative mother have Rh isoimmunisation.  
These neonates are screened with blood group and typing & Direct Coomts Test (DCT) on cord 
blood.  In addition, PCV and serum bilirubin also estimated in  same sample.  Once these are 
diagnosed, reticulocyte count is done before every exchange transfusion is carried out.  
Intensive phototherapy from birth and continued with serial bilirubin monitoring.  Bilirubin 
level of 0.5 X birth weight is rough guidance for phototherapy. Serum bilirubin of more than 
1% of birth weight is a rough guidance for exchange transfusion.  Immunoglobulin can be 
started at a dose of 500 mg/kg  Q 12 hrly for two doses after the first transfusion.
ABO incompatibility:-
ABO incompatibility is the most common cause of hemolytic disease of newborn. The 
discovery of ABO blood grouping systems in 1901 by Karl Landsteiner was a major 
breakthrough in hematology. 
Apart from the ABO systems, he also reported antibodies against these A, B antigens.  
This landmark discovery of antibodies against blood group antigens is the basis for various 
blood group incompatibility disorders.  We know that ‘O’ group individuals have anti-A, anti-B 
antibodies.  This incompatibility is one of the reasons for Hemolytic disease of Newborn.
In 1761, Morgagni described hemolytic disease as icterus gravid neonatarum. 
Historically, the most important cause of severe jaundice was Rh isoimmunisation.  After the 
advents of anti-D prophylaxis in Rh negative woman, ABO incompatibility became the most 
common cause of hemolytic jaundice. Hemolysis occurs due to ABO incompatibility where 
anti-A, anti –B antibodies cross the placenta & sensitise the A / B / AB infant. In A /B  group 
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mother , antibodies are IgM variety whereas IgG are formed in O group mothers. Only a small 
amount of antibodies cross placenta & bind fetal RBC where the expression of A/ B antigen is 
less mature. Therefore affected neonates will have less significant hemolysis compared to Rh 
affected neonates. ABO can affect the first born & as well as subsequent newborns with equal 
frequency. Due to low antigenicity it is not possible to evaluate ABO hemolytic disease 
antenatally.
ABO incompatibility protects against Rh isoimmunisation since anti-A, anti-B 
antibodies in mother destroys incompatible fetal cells which enters maternal circulation. Due to 
unexplained reasons B-O incompatibility is more severe than A-O incompatibility.
Sensitisation of the mother can happen by 
 Previous transfusion
 Ectopic pregnancy
 First trimester abortion
 Amniocentesis
 Manual extraction of placenta
 Extensive version procedure
Minor group incompatibility, G6PD deficiency, hereditary spherocytosis should all be 
considered in infants with family history / geographical origin.
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Clinical examination of jaundice:
Prerequisites:
Examination in good day light. Skin should be blanched with digital pressure. colour of skin & 
subcutaneous is noted. Using a rough guidelines bilirubin level estimated as noted in the picture. 
Yellow discolouration below thigh needs for emergency biochemical confirmation of bilirubin 
level.  
Kramer et al classically described the clinical examination of jaundice.based on skin 
staining of bilirubin which is used as a clinical tool to assess level of jaundice. This 
development of staining progresses in a cranio caudal direction.
Kramer’s rule is not applied if 
 Neonate is on  phototherapy
 Newborn Is dark skinned 
There are more objective methods of measuring the skin colour and pigmentation. This includes 
 spectrometry and 
 trans bilinometer  
35
Bilirubin toxicity:-
The predominant toxicity of unconjugated bilirubin is through neurological injury.  
There are multiple mechanisms through which the bilirubin enters the brain, as previously 
elucidated, bilirubin in circulation is bound to albumin complex.  The unbound excessive  
lipophilic  free bilirubin enters the blood brains barrier and precipitate on lipid membranes in 
low pH.  Another propounded theory is that the albumin-bilirubin complex transfers the 
bilirubin by cellular surface contact.  This mechanism is enhanced by a damaged BBB.
FIG : 6 KRAMER’S RULE - Clinical diagnosis of NNH
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 Hypoalbuminemia: Estimation of albumin level is also important in 
determining free lipophilic bilirubin level.
 Low pH : Respiratory acidosis, sepsis, hypoxia,seizures.
 Vascular injury in the BBB can precipitate cross over.
 Preterm delivery: Immature BBB.
 Certain drugs: Sulphonamides displace the bilirubin from albumin complex.
 Free Fatty Acid at high   molar ratios of FFA : albumin also displaces 
bilirubin.
Clinical significance: NNH is very common.  But still neurological injury is rare.  There is a 
mismatch between the level of hyperbilirubinemia and the occurrence of its encephalopathy. 
This variability between bilirubin level and predisposition into encephalopathy is explained by 
the following factors which increases or influence the entry of bilirubin into the neuronal tissue.
Rate of rise of bilirubin:
It has been postulated that the rate rather than level of hyperbilirubin is major factor 
which pushes lipophilic bilirubin across the BBB.  Hence there is increased risk of kernicterus 
in hemolytic disease of newborn.  Presence of these risk factors can lower the threshold of 
hyperbilirubinemia causing kernicterus.
Mechanism of bilirubin neurotoxicity:
1. Neuro transmission interruption
2. Mitochondrial dysfunction
3. Membrane impairment of cells
4. Interface with enzyme activity (binding to receptor site)
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Histopathology:
There is characteristic neuronal necrosis and yellow staining of bilirubin in 




 Anterior horn cells
There is sparing of cerebral cortex.
Extra CNS lesions are seen such as 
 Renal tubular necrosis
 Intestinal mucosal desposits
 Pancreatic deposits
BIND (Bilirubin Induced Neurological Delay) can be
             - acute
             - chronic
Acute Bilirubin encephalopathy:
Severe hyperbilirubinemia of serum bilirubin >20mg/dl can develop signs of acute 
bilirubin encephalopathy. If undiagnosed may end in kernicterus. Manifest clinically as three 
phases based on its progression and evolution.  Due to the affliction of hippocampal, midbrains 
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and cerebellar areas, symptoms are also predominant based on tone and reflex (clinical 
significance). Mortality and morbidity increases with each progressing phase.
Phase I (1st 1-2 days)
 Hypotonia, 
 poor suck, 
 lethargy (excessive sleepness)  
 absence of startle reflex
 weakness
Phase II ( middle of 1st wk ) 
 irritability, 
 Hypertonia of extensor muscles (opisthotonus, occulogyric crises, rigidity and 
retrocollis)
 fever & seizures         
Mortality in this phase is very high and those babies who survive this phase progress on to 
chronic encephalopathy (Kernicterus).
Phase III ( after the first wk)
 Opisthotonus, 
 high pitched cry,
 apnoea , 
 seizures, 
 coma and death.
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Chronic bilirubin encephalopathy (Kernicterus)-
          Usually evident by 3 years of age. The term Kernicterus in the clinical scenario should be 
used to denote the chronic and permanent sequalae of bilirubin toxicity. Clinical features are 
athetosis, sensorineural deafness, limitation of upward gaze, dental dysplasia, sometimes 
intellectual deficit.
Prevention of toxicity:
The prevention of bilirubin toxicity is remarkably correlated to the etiology and factors 
affecting bilirubin cross over.  The rate of bilirubin production is to be brought down.  
Immunoglobulin in isoimmune HDN, discontinuation of sulphonamide like drugs, increased 
feeding, increased calorie to reduce enterohepatic circulation of bilirubin, prevention of pH, 
hypoxia and acidosis.
            Management of hyperbilirubinemia includes identification of at risk neonates, 
identification of the cause, deciding when to start & stop treatment and watch for severe 
hyperbilirubinemia, also decides the  time of discharge
Removal of excess bilirubin: -
                     >Phototherapy,
                    >Exchange transfusion
Historical therapies: 
Phenobarbitone   --  increases conjugation
Oral agar    -- reduces enterohepatic  circulation
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Metaloprotoporphyrin--  inhibits heme oxygenase
As per AAP recommendation, jaundice within 24hrs of life in  healthy term newborn is 
always pathological. Newborn’s risk of developing significant hyperbilirubinemia classified as 
low, intermediate or high, depending on the rate of rise of bilirubin level, as shown in the 
bilirubin chart above. Conjugated hyperbilirubinemia is always pathological. But there is no 
direct toxicity due to increased conjugated bilirubin level to the brain cells. In term baby with 
hemolysis, a bilirubin level above 20mg/dl (342µmol/L) is of concern.
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Fig : 6-a BILIRUBIN STAINING IN THE MID BRAIN  
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Fig : 6-b  BILIRUBIN GROSS HPE DEPOSITS IN GLOBUS PALLIDUS
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Fig : 7  HOUR SPECIFIC BILIRUBIN NOMOGRAM
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FIG : 8 AAP GUIDELINES FOR PHOTOTHERAPY IN  NEONATES  




Identifying the cause of NNH is vital in the treatment of these neonates. The following basic 
tests are done to classify and treat the NNH accordingly.
1. Maternal blood group
2. Baby blood group
3. Cord bilirubin and venous bilirubin levels
4. Hemoglobin/ CBC
5. Peripheral smear and reticulocyte count
6. Coomb’s Test
These tests are fairly conclusive in diagnosing the cause of the child’s NNH. 
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FIG : 9 DIAGNOSTIC WORK UP  OF NEONATAL HYPERBILIRUBINEMIA
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FIG : 10  DIRECT COOMBS TEST
                 
In the direct antiglobulin test( direct coombs  test) , antibodies of Ig G type is elicited on 
the washed RBCs of babies. Often this is weakly positive DCT. Alloantibodies anti-A or anti-B 
can be eluted from the RBCs of the baby. The presence of free anti A and anti –B allobodies in 
the baby’s serum can be assessed by indirect antiglobulin test. In clinically significant A-O or 
B-O incompatibility, nearly all the babies have this test positive.  More spherocytes & stonger 
antiglobulin reaction are seen in those babies with jaundice requiring phototherapy or exchange 
transfusion. Many of the ABO incompatibile babies do not require therapy, except those with 
hyperbilirubinemia
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PERIPHERAL  SMEAR STUDY:
Anemia is usually absent or mild. In majority, babies exhibit an increased numbers of  
nucleated RBCs and increased  reticulocyte count ( 5- 15 % )  in the peripheral smear. Partial 
membrane loss results in  microspherocytes which are charecteristics on the peripheral smear. 
Spherocytes are dense , staining spherical red cells with normal or slightly decreased MCV 
without any central pallor
                      
FIG 11
 Long arrow- reticulocyte premature RBC
 Short arrow- spherocyte RBC
 Double arrow- polychromatophilic RBC
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Phototherapy:
The most efficient are the blue lamps with peak output at 425 – 475 nm which is the 
maximum absorption peak of bilirubin.  Due to the skin texture, fiberoptic phototherapy
(phototherapy blankets) reduce bilirubin level relatively less in term babies. Phototherapy is 
initiated based on age of the neonate & the total serum bilirubin level. The power output of the 
light (irradiance) is directly related to the distance between the lights & the neonate.
Photo isomerization: 
                         Photo isomerisation happens at low dose phototherapy (6 microwatts/sq.cm
/nm).  Natural isomer of unconjugated bilirubin is converted to polar isomer which is less toxic 
and without conjugation excereted in to the bile.  If baby is not passing stools, photo isomer is 
changed back to unconjugated bilirubin and gut reabsorbs it after 12 hours of phototherapy, 
photo isomers constitute 20% of total bilirubins.
Structural isomerisation: 
Irreversibly converted to lumirubin by cyclization.  Also excreted without conjugation 
into bile, rapidly.  During phototherapy 2% to 6% of serum bilirubin is lumirubin. At a dose of 
6 - 12 µwatts/sqcm/nm, this is the significant way of lowering serum bilirubin levels.
Photo oxidation: 
Photo oxidation is a slow process that converts bilirubin to polar products
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Technique of phototherapy:
Effect of phototherapy depends on irradiance, distance from the infant (inversely 
related) light spectrum and extent of skin area exposure.
Conventional phototherapy when kept at 45 cm above the baby,   at 8 – 10 
µwatts/sq.cm/nm , at 430 to 490 nm deliver the irradiance of optimal spectrum.  Lactation is 
continued ,  no additional fluid is  needed.
Intensive phototherapy provides 30µwatt/sq.cm/nm at the same spectrum and is 
indicated in:
1. rapid rise of the serum bilirubin level
2. the serum bilirubin level is within 50µmol/L (which may need exchange 
transfusion after 72 hours)
3. single phototherapy fail to respond (even after 6 hours of starting 
phototherapy, rise or absence of falling trend of serum bilirubin)
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FIG : 12 PHOTOTHERAPY  UNIT
FIG : 13 DURING PHOTOTHERAPY
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General care: 
1) Maximum area of exposure
2) Supine portion in thermo neutral environment
3) Eye protection (Eye covers)
 Hydration to be monitored
 Turn the neonates every 2 hours
 5 – 8 cm space between it and the incubator if used 
 10 – 20% extra fluid in addition to usual requirement is to compensate
insensible water loss in warmer  
 don’t  interrupt phototherapy for feeding, continue IV /enteral feeds.
Disadvantages of phototherapy:
 Separation from parents as it is continuous
 Bronze baby syndrome 
 Retinal damage, skin rash, burns, loose stools, thermoregulation instability, 
dehydration
The total serum bilirubin should decline by 1-2 mg/dl (17-34µmol/L) within 4 - 6hrs
Tests in all babies with significant hyperbilirubinemia:
Serum bilirubn, PCV, blood group ( mother and baby), coombs test, complete blood 
count, blood G6PD levels, cultures of blood, Urine & CSF (if meningitis is suspected).
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IV Immunoglobulin:
500mg/kg over 4 hours – can be an adjunct to intensive phototherapy in Rh & ABO   
incompatibility when serum bilirubin rise by > 8.5 µmol/L per hour continuously.
Causes for prolonged jaundice:




Failure of phototherapy: Failure to reduce bilirubin of 1 – 2 mg/dl after 4 – 6 hours of 
phototherapy and/or to maintain the bilirubin lelvel below exchange transfusion.
Exchange transfusion:
For ABO isoimmunisation, fresh whole blood of mother’s blood group & baby Rh group 
is used.  For Rh isoimmunisation, fresh whole blood of baby blood group &   mother Rh group 
is used .  Baby’s blood group is used in other situations.
Exchange transfusion removes RBCs coated with antibodies, unattached antibodies 
removal of hemolysed RBCs , donor RBCs that lack sensitizing antigens are transfused. 
Extravascular bilirubin equilibrates rapidly following the removal of bilirubin from the plasma  
bilirubin level reaches 60% of pre exchange level, within half an hour. Rapid transfer of 
bilirubin into vascular bed. The post exchange bilirubin level if increased is due to 
 Lysis of senescent donor RBCs
 Hemolysis of antibody coated RBC sequestered in bone marrow or spleen
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 From early labelled bilirubin
Indications of exchange transfusion :        
 hydropic newborn babies with hemolytic disease –correction of anaemia &
to improve heart failure
 Cord Blood Bilirubin > 4.5/dl & HB < 11g/dl 
 Rate of rise of bilirubin>1mg/dl/hr, even on phototherapy
 Hemoglobin level is between 11 & 13 mg/dl
 Bilirubin level >0.5mg/dl/hour










SOURCE OF  DATA:
All  healthy term neonates admitted in the NICU of Government 
Mohan Kumaramangalam Medical college and Hospital were screened for ABO 
incompatibility and included based on the following criteria.
STUDY DESIGN
Type of study      : Prospective  Observational Cohort Study
Period of study    : One Yr from September  2014   to August  2015     
Total newborn screened   : 6200 babies
Study population      : 820 full term healthy newborn babies born to O group 
mothers delivered in GMKMCH, Salem
Inclusion criteria:
 Healthy  term babies delivered within the period of study
 Born  to mothers with O positive blood group  
 Appropriate for age 
 Small for gestational age
Exclusion criteria:
 Rh incompatibility 
 Significant illness requiring NICU admission
 Major congenital malformation
 Those who didn’t give consent 
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METHOD OF  COLLECTION OF DATA  :      
3 ml blood drawn from the mother for blood grouping & typing. After  getting consent, 
routinely 2ml of blood is drawn in a sterile manner from the umbilical cord & veni puncture on 
subsequent analysis at 24hrs , 48 hrs & 72 hrs of life from those neonates. All these samples 
were taken with sterile disposable % ml syringes & needle. The test tubes contain ethylene 
diamine tetra acetic acid (EDTA) & they were taken to the lab immediately.
A predrawn   proforma is explained to the mother or the caregiver. Informed consent 
regarding participation in the study is obtained in the regional language (Annexure- 1 ). All 
details are filled in the proforma.
Babies are clinically assessed for age , sex, gestational age, birth weight, previous 
history of jaundice in the family, day of onset of jaundice, pattern of feeding, fever, other 
neurological symptoms.





 extravasation of blood (cephalhematoma / subgaleal bleed) 
 excessive bruising,
 neurological signs like opisthotonus
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Investigations done:
Blood was collected in sterile 2 ml syringes and sent in sterile test tubes for the biochemical 
tests. EDTA tubes were used for peripheral smears.
Mother’s blood : Blood grouping & Rh typing is done for the mother.
Cord blood : cord blood sample was taken & sent for 
 blood grouping & Rh typing and Direct coombs test(DCT)
 cord blood bilirubin level estimation
neonatal venous sample blood is later sent for:
 serum bilirubin level at 24hrs, 48hrs & 72hrs
And if  Direct coombs test is positive, sent for 
 reticulocyte count, 
 peripheral smear study
 complete blood count
Management :
Babies were followed up daily for the progression of icterus & for the intervention. The levels 
of cord blood bilirubin, 24hrs bilirubin level and the development of neonatal 
hyperbilirubinemia were correlated and monitored. According to these parameters and also their
gestational age, day of life, & presence of risk factors, babies were treated with phototherapy 
and if necessary with an exchange transfusion.
All these monitored parameters and the respective intervention in each of the neonate was 




OBSERVATION  AND  RESULTS
Total number of deliveries during the study period is 6200. Out of these delivered  mothers  
3286(53%) were  O group mothers. Rest of them are A(24%) , B(20%) , AB(3% ).Based on our 
inclusion & exclusion criteria, our cohort study covered a total of 820  healthy term newborns 
born to O group mothers. There were a total of 94 cases of NNH. 11 cases belonged to the O 
group. Hence they were taken as the control group in ABO incompatibility.
Analysis of our data was done under the following heads:
Total cohort strength : 820
Total no of NNH cases : 94
NNH cases with ABO incompatibility : 83
Control group- O grp with NNH : 11
Total no of cases  for phototherapy : 15
Total no of cases with exchange transfusion : 2
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The incidence of NNH due to ABO incompatibility was  10.1 %.
The no of peripheral smear positive cases (reticulocytes more than 5-6%)) were 9. 
The mean reticulocyte count in these smear positive cases was 7.1 %.
The mean no. of days of phototherapy was 1.6 days. The time of start of the phototherapy was 
analysed.
TABLE 1 : SPLIT UP OF NNH CASES.







FIG 15 :  NNH  DISTRIBUTION
Positive Negative
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FIG  16:  NNH in ABO incompatibility in our study
normal neonates
nnh due to ABO incompatobility














FIG  17  :  SEX AND NNH
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TABLE 3 :  PREVALENCE OF SEX




















NNH + NNH  -
NNH + NNH  - TOTAL Chi square P value
Male 52 399 451 11.53%
0.004 0.947
Female 42 327 369 11.32%
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TABLE 4 :  CORELATION BETWEEN SEX AND NNH
Sex/NNH In 
Baby Group





N % N % N % N %
Male 26 50 23 44.2 - 3 5.8 52
15.94 0.003**
Female 19 45.24 13 30.95 2 4.76 8 4.76 42
FIG 19 :   SEX AND NNH
Out of the 820 babies, there were 451 males   &   369 female babies.    Out of 451 male 
babies,  49  developed hyperbilirubinemia, while   out of    369 female neonates 45  had 
hyperbilirubinemia.
This difference in sex ratio was statistically insignificant (p values <0.05). Hence there 
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Assisted Breech 13 1.59
Total 820 100
Mode of delivery:













P valueN % N % N %
Male 25 48.08 24 46.15 3 5.8 52
0.119 0.942
Female 19 45.24 20 47.62 3 7.14 42


















Normal LSCS Assisted breech
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TABLE 7 : BIRTH WEIGHT AND NNH
Incidence of NNH in different birth weight groups was analysed.
Birth weight No Percent
< 2.5 77 9.39
2.5 - 2.8 424 51.71
2.9 - 3.2 296 36.10












TABLE  8  : STATISTICAL ANALYSIS OF NNH IN BIRTH WEIGHT GROUPS
Birth weight
NNH
Total Chi square PPositive Negative
N % N %
< 2.5 14 18.18 63 81.82 77
3.88 0.275
2.5 - 2.8 46 10.85 378 89.15 424
2.9 - 3.2 32 10.81 264 89.19 296
> 3.2 2 8.70 21 91.30 23
Total 83 10 737 90 820
FIG 23 : BIRTH WEIGHT & NNH . Due to the equal incidence of NNH in these weight 

























TABLE 9 : BLOOD GROUP PREVALENCE:






O group was the most prevalent. Babies with NNH in O blood group were taken as the control 











TABLE `10 : BLOOD GROUP  AND  NNH
Baby GRP
NNH
Total Chi square PPositive Negative
No % No %
A 45 27.61 118 72.39 163
115.83 < 0.001**
B 36 25.00 108 75.00 144
O 11 2.15 500 97.85 511
AB 2 100.00 2
Total 94 11.5 726 88.5 820























TABLE 11: STRENGTH OF CORELATION BETWEEN BLOOD GROUP & NNH
Baby GRP
NNH
Total Chi square PPositive Negative
No % No %
A,B,AB 83 26.86 226 73 309
115.83 < 0.001**
O 11 2.15 500 98 511
Total 94 11.46 726 89 820
FIG  26 :  CORELATION BETWEEN BLOOD GROUP  AND NNH
These charts show the significant correlation between NNH in ABO incompatible groups and 





















The coomb’s test was done in all the cases of NNH. There were 15 positive cases. These babies 
turned out to be those with very high bilirubin levels requiring phototherapy.
FIG  27 : Coomb's test 
coombs test positive cases




ANALYSIS OF PERIPHERAL SMEAR REPORTS.
Those with premature RBCs more than 6% were positive smears
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TABLE 12 : TREATMENT OF NNH
TREATMENT MODALITY
Total    no.
Total NNH in ABO 
incompatibile
PERCENTAGE
Phototherapy required 15 83 18.1%
Exchange transfusion 2 83 2.4%
TABLE 13 : PHOTOTHERAPY DETAILS
Phototherapy NO. Percent
Required 15 1.83
Not Required 805 98.17
Total 820 100
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TABLE  14:  DAY OF INITIATION OF PHOTOTHERAPY
Day phototherapy started Frequency Percent Valid Percent
1 7 0.85 47
2 5 0.61 33
3 3 0.37 20
Total 15 1.83 100
System 805 98.17
820 100.00






N0 % N0 %
1 4 44.4 3 50.0 7 46.7
2 3 33.3 2 33.3 5 33.3
3 2 22.2 1 16.7 3 20.0
Total 9 100.0 6 100.0 15 100.0
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FIG  31  : DAY OF INITIATION OF PHOTOTHERAPY
15, 2%
805, 98%






























No. % No. %
A 6 13.3 39 86.7 45
B 9 25.0 27 75.0 36
O 11 100.0 11
AB 2 100.0 2




















FIG  32  : BLOOD GROUP AND PHOTOTHERAPY
Required Not required
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CORELATION  OF THE CORD BLOOD BILIRUBIN AND NNH LEVELS.
For the establishment of the strength of correlation between two variables the following 
parameters are statistically assessed.
Sensitivity = / (True Positive + False Negative)*100
Specificity = TN/(TN+FP)*100
Positive predictive value = TP / (TP+FP)
Negative Predictive value = TN / (TN+FN)
TABLE 17 :  STATISTICAL VALUES
Test + Test -
Diseased                True Positive False Negative Sensitivity
No diseased False Positive True Negative Specificity
Positive predictive value Negative Predictive
After calculating these values, each, for
1. Cord Blood Bilirubin and NNH
2. 24 hrs bilirubin and NNH
Cut off values for the same were calculated using the strength of the Negative Predictive Value 
in  Receiver Operating Curves (ROC).
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FIG  33 : ROC CURVE FOR CORD BLOOD BILIRUBIN
ROC Curve













TABLE 18 : CBB CUT-OFF DETERMINATION
NNH Predicted Group Membership Total
Original Positive Negative
Positive 80 14 94
Negative 206 520 726
Sensitivity = 85.11
Specificity = 71.63
Positive predictive value = 27.97




Coordinates of the Curve for estimating Cut- off  for CBB values
Test Result Variable(s): CBB
Positive if 
Greater Than or 





















The test result variable(s): CBB has at least one tie between the positive actual state group and 
the negative actual state group.
a  The smallest cutoff value is the minimum observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. All the other cutoff values are the averages of 
two consecutive ordered observed test values.
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FIG   34  : ROC CURVE FOR 24 HRS
ROC Curve













TABLE 20 : CUT- OFF FOR 24hr SRB
NNH Predicted Group Membership Total
Original Positive Negative
Positive 84 10 94
Negative 226 500 726
Sensitivity = 89.36
Specificity = 68.87
Positive predictive value = 27.10
Neg Predictive = 98.04
CUTOFF VALUE = 4
86
TABLE 21
Coordinates of the Curve for estimating Cutt-off values for 24 hrs bilirubin level








































The test result variable(s): 24hr SRB has at least one tie between the positive actual state 
group and the negative actual state group.
The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus 1. All the other cutoff values are the 
averages of two consecutive ordered observed test values.
This implies that there is significant correlation between cord blood bilirubin & neonatal 
hyperbilirubinemia in the first 2 days screening values. Also level of cord blood bilirubin is
found to be higher in these newborns with significant hyperbilirubinemia.
In order to predict cut off values for CBB levels, receiver operating curve analysis was 
used. Based on this, CBB< 2.1 mg/dl was found to have sensitivity of 85.11% & specificity of 
71.63 %   positive predictive value of 27.97 % and a negative predictive value  of 97.38 %
For day1 bilirubin cut off levels< 4 mg/dl , similar ROC curve was used to estimate 
the value as   sensitivity 89.36 % , specificity 68.87 %, positive predictive value of 27.10 %  & 





The problems we face in managing NNH are multifold. Many early discharged neonates 
were readmitted for significant hyperbilirubinemia in the 1st week of life. This is a major 
financial and  manpower strain on the government hospital. 
According to AAP guidelines, all neonates discharged within 48hrs must be reviewed 
after 2-3 days for compulsory bilirubin level estimation. The logistics of this compulsory 48 
hour review is not possible in our country and that too in a government hospital milieu.  
Therefore critical values of CBB are needed to differentiate early safe discharge of neonates
and those requiring 48 hours monitoring.
Our study has strived to reduce these readmissions by CBB correlation of NNH. Due to 
the high negative predictive value for the cutoff levels, we can be very sure that those neonates 
below the cutoff can be safely discharged with least possibility of readmission.
Failure to detect NNH early on leads to bilirubin encephalopathy or Kernicterus a 
fully preventable debilitating disorder of the child.  Cord blood screening can identify these 
NNH cases for early phototherapy,  thereby fully  preventing Kernicterus.
Compared to conventional venous sampling, cord blood screening is Less Invasive 
thereby easier to perform in various peripheral centers and also helps in  reducing  the sepsis 
rate by being non invasive.
Our methods of screening and management are very cost effective and easier to 
perform.
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In our study, the aim was to assess the predictive ability of cord blood bilirubin & day 1 
bilirubin levels in neonatal hyperbilirubinemia prediction.
During the course of the study there were a total of 6200 deliveries during the period of 
our study. Out of these we take upto into consideration of those healthy term neonates with 
ABO incompatibility only. Neonates with comorbid factors are excluded. After all these 
exclusion criteria , the total number of new born enrolled into study were 820.  Among these 
820, we had total number of 83 NNH.  Thereby getting the incidence of 10.1% of NNH in 
ABO incompatible population.  
Even though the prime aim was to find out correlation between cord blood bilirubin and 
NNH, we also analysed the relationship between sex of the babies and NNH, birth rate of 
babies and NNH, mode of deliveries a nd NNH.  Also the percentage of phototherapy required 
and percentage of exchange transfusion totally carried out in the study are also analysed. 
Regarding the sex of the child, in our study, there were 52 male child with ABO with 
NNH  and 42 female child with ABO with NNH.  After statistical evaluation of these children, 
the sex and blood group of NNH is found to have no correlation. .  In the course of the study 
sex wise distribution, birth weight wise distribution was also assessed & there was no 
correlation between these two parameters and neonatal hyperbilirubinemia
Studies by Maisels & Kring& Satrya et al also predict more risk of NNH in the male 
child. 
Awasthi & rahman(21)Rosami & Mehrabi ,Taksande show that there is no correlation 
between birth weight or sex of the baby. 
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Our study also shows no statistically significant correlation between the birth weight or 
sex of the baby in NNH.
With regard to the birth weight distribution, comparison made between each of these 
birth weight groups.  Having these babies into consideration, AGA & SGA babies were 
evaluated.  Around 8 neonates developed NNH out of 80 SGA babies. Out of 740 AGA babies, 
12 developed NNH.  ABO incompatibility causing NNH is 83.  Of this 83 the number of OA 
incompatibility is 45 ( incidence 54.2%) in 83 when compared to the number of OB 
incompatibility 36 (43.4%) which is less than that of OA.  
TABLE 22  : BIRTH WEIGHT AND  NNH
Birth weight No: of babies NNH %
SGA(< 2.5kg) 80 8 10%
AGA(>2.5 kg) 740 60 12%
Incidence of NNH in our study is 11.46% including the control O group.  26 (50%) 
males belonging to ‘A’ group developed NNH. Out of which 4 required phototherapy. 19 
(45.24%) females belong to ‘A’ group developed NNH and 2 required phototherapy. 
There were 2 female cases of O-AB incompatibility which accounted for 4.8% 0f NNH.
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Male Percent Female percent
male Percent
female percent
A 26 50 19 45.2
4 15.4
2 10.5
B 23 44.2 13 30.95
5 21.7
4 30.8
O 3 5.8 8 19.05
- -
- -
AB - 2 4.8
- -
- -
23 males belonging to ‘B’ group developed NNH and out of this 5 required 
phototherapy.  13 females belonging to ‘B’ group developed NNH and 4 required phototherapy.  
(30.95%)  this implies O – B incompatibility is severe than OA.    
The reasons for Day 1 Bilirubin being given such importance is to include, non 
institutional deliveries where CBB screening was missed.
In our study the Receiver Operating Curve (ROC) was very essential. All parameters 
were plotted on the curve and the cut off values were statistically obtained.
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The probability that a neonate with CBB > 2.1 will go on to hyperbilirubinemia was 
27.97 % (positive predictive value). 
The probability of a baby of CBB < 2.1 mg/dl not getting hyperbilirubinemia was 
97.38%.( negative predictive value)
The probability that a neonate with Day 1 bilirubin > 4 will go on to hyperbilirubinemia 
was 27.10 %(positive predictive value). 
The probability of a baby of Day 1 bilirubin < 4 mg/dl not getting hyperbilirubinemia 
was 98.04 %.( negative predictive value)
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TABLE  24:  COMPARISON  WITH  PREVIOUS  SIMILAR  STUDIES:
STUDIES YEAR NO. OF CASES UMBILICAL CORD 
BILIRUBIN
Knudson et al 1989 291 <1.17mg
>2.34mg
Rosenfeld J et al 1986 - <2mg
>2mg
Bernaldo et al 2004 380 >2mg





Amar t et al 2005 200 >2mg dl
OUR STUDY 2014 820 >2.1
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TABLE 25 :  STUDIES ON THE PREDICTIVE ABILITY OF CORD 
































































Amar Taksande et 
al(2005)
>2 89.5% 85% 38.8% 98.7%
Zakia Nahar et al 
(2009)
>2.5 77% 98.6% 96%
Knudsen(1989) >2.35 13% 99% 85% 72%
Rudy Satrya et al(2009) >2.54 90.5% 85%
Sun et al (2007)
>2 68% 45.08%
OUR STUDY >2.1 85.11% 71.63% 27.97 97.38
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1.3 73 0 73 - - - -
1.4 73 0 73 - - - -
1.5 73 0 73 - - - -
1.6 72 0 72 - - - -
1.7 72 0 72 - - - -
1.8 12 0 12 - - - -
1.9 72 0 72 - - - -
2.0 71 0 71 - - - -
2.1 77 5 72 0 72
2.2 83 10 73 0 73
2.3 78 5 73 0 73
2.4 15 15 0 1 14 6.7
2.5 5 5 0 0 5
2.6 - - 0
2.7 - - 0































2.9 - - 0
3.0 - - 0
3.1 5 5 0 1 4 20
3.2 15 15 0 5 10 33
3.3 5 5 0 2 3 40 1
3.4 10 10 0 4 6 40 1
3.5 4 4 0 2 2 50
Total 820 83 15 2
Another significant importance of CBB prediction of NNH is in planning for elective 
sterilization. Presently whenever a O group mother delivers, we do not advise sterilization 
immediately, because the baby may develop pathological hyperbilirubinemia due to ABO 
incompatibility. But with the help of CBB, (if <2.1mg/dl ) sterilization can be advised earlier to 
the mother(puerperal) or the father( NSV- No Scalpel Vasectomy) if the levels are below the 
cut off values
LIMITATIONS: 
 In our study only healthy  term babies were taken into consideration.
 A much bigger cohort study over a longer period  of time including all cases of NNH  






NNH  is a very common problem. It is also the most common cause of readmission in 
the first week of life.  97.38% negative predictive value implies that neonates with CBB < 2.1 
mg/dl with ABO in compatibility are very unlikely to receive any further intervention.  These 
babies can be safely discharged early.
It also implies that these children with ABO and CBB bilirubin >2.1, need monitoring 
for any future early intervention.  Likewise, 24 hr bilirubin level cut off values have been fixed 
at 4mg/dl for predicting NNH severity.  Those babies with 24 hr levels > 4mg/dl must be 
periodically screened for NNH. Thereby reducing the chance of Kernicterus. 
Being less invasive, easy to perform, and cost effective, CBB screening in NNH is very 
economical.
Being easy to perform these values may be extrapolated in the outreach rural population 
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ANNEXURE – 1
     PROFORMA
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CORD BLOOD BILIRUBIN &  NEONATAL HYPERBILIRUBINEMIA IN ABO 
INCOMPATIBILITY 
PATIENT PROFILE - PROFORMA
SERIAL NO: LOST to FOLLOW UP
• BABY OF:                IP NO:                      SEX:           
• ADDRESS : 
• WEIGHT: SGA /AGA / LGA SINGLE / TWIN
• DATE OF BIRTH:                       MODE OF DELIVERY: 
• OBSTETRIC SCORE:                                        LMP :                           EDD:
• H/O JAUNDICE IN SIBLING IN NEONATAL PERIOD:
• H/O MATERNAL DRUG INTAKE:
• BLOOD GROUP OF MOTHER:                                            BABY:
• APGAR :                    1’                                   5’
• GESTATIONAL AGE (NEW BALLARD SCORE):
• ANY CONGENITAL ANOMALY:
• CORD BLOOD BILIRUBIN LEVEL:
• SERUM BILIRUBIN LEVEL                   TOTAL                INDIRECT            DIRECT                      
                                AT 24HRS :             
                                48HRS:           
                                72HRS:                                                                                                                    
• DIRECT COOMBS TEST:
• PERIPHERAL SMEAR STUDY:
• DAY OF APPEARANCE OF JAUNDICE:
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   PHOTOTHERAPY:  YES / NO
                         DAY OF STARTING PHOTOTHERAPY    DAY 1- DAY2 - DAY3-
                         DURATION OF PHOTOTHERAPY –
 EXCHANGE TRANSFUSION:  YES  / NO
 DATE OF DISCHARGE:
INFORMED CONSENT FOR PARTICIPATION IN THE STUDY
I,                      W/O                                      hereby consent to participate 
in this study where blood samples may be collected from the cord blood as well 
as venous blood to evaluate level of jaundice in my baby. I am fully aware that 
NO new, adventurous intervention is planned on my child as part of this study. 
Whatever treatment is given to my child based on these blood results is fully in 
the best interest of the child & is also the established treatment method in this 
hospital. 
x¥òjš got«
ÂUkÂ                                      f/bg.                                    M»a eh‹ vdJ 
FHªijia Ïu¤j gçnrhjid¡F« mj‹ _y« el¡F« Ïªj MŒÎ¡F« KG kdJl‹ c£gL¤j r«kÂ¡»nw‹. Ïªj 
MŒéš, bjh¥òš bfhoæèUªJ«,  Ïu¤j ehu§fëèUªJ« Ïu¤j vL¤J vdJ FHªijæ‹ fhkhiy 
mséid bjçªJ bfhŸs r«kÂ¡»nw‹. Ïªj gçnrhjidæš fhkhiyæ‹ msÎ mÂfkhf ÏUªjhš, mj‰F 
jFªj  bjçªj, kUªJtkid tiuKiw¡F  c£g£l Á»¢iræid brŒJ bfhŸs r«kÂ¡»nw‹. Ïªj MŒé‹ 
_y« vdJ FHªij¡F vªjéj òÂa ã%Ã¡fglhj Á»¢ir KiwÍ« më¡f nghtÂšiy v‹gijÍ« m¿nt‹.   





IP No. Sex Birth weight Baby GRP CBB 24hr SRB 48 hr SRB 72 hr SRB Phototherapy photoday photoduration day 4 SRB ET coombs RETIC PSS Delivery NNH Baby GRP Birth weight
11202 M 2.5 A 2.4 4 8 12 NP . ˉ N N H 1 2
11204 M 2.6 A 2.4 4 8 11 NP . ˉ N L H 1 2
11205 M 2.7 A 2.4 4 6 12 NP . ˉ N L H 1 2
11206 M 2.5 A 2.4 4 7 11 NP . ˉ N AB H 1 2
11209 M 2.6 A 3.5 5.5 11 11 P 2 1 dct+ 6% N N H 1 2
11213 M 2.7 A 3.5 6.5 9 14 P 3 2 dct+ 6% S+ L H 1 2
11215 M 2.5 A 2.4 4 7 11 NP . ˉ N N H 1 2
11219 M 2.6 A 2.4 12 10 15 P 1 3 dct+ 9% S+ N H 1 2
11223 M 2.7 A 2.4 4 8 12 NP . ˉ N AB H 1 2
11226 M 2.1 A 3.4 12 14 17 P 1 3 23 done dct + 9% S+ N H 1 2
11229 M 2.1 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 1
11236 M 2.9 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 1
11231 M 2.1 O 1.5 3.7 7.5 8.7 NP . ˉ AB N 2 1
11235 M 2 O 1.6 3.8 7.6 8.8 NP . ˉ N N H 2 1
11238 M 2.2 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 1
11245 M 2 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 1
11240 M 2 O 2 4.2 8.4 9.2 NP . ˉ N L H 2 1
11237 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 1
11243 M 2.2 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 1
11248 M 2 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 1
11256 M 2.1 B 3.2 12 14 17 P 1 2 dct+ 9% S+ L H 1 1
11253 M 2 B 3.2 4 8 11 NP . ˉ N L H 1 1
11257 M 2 B 3.2 11 10 14 P 1 2 dct+ 8% S+ L H 1 1
11259 M 2.1 B 3.2 5 7 11 NP . ˉ N L H 1 1
11262 M 2.2 B 3.2 5.4 11 15 P 2 1 dct+ 6% N L H 1 1
11264 M 2 B 3.2 6.6 9 13 NP . ˉ N N H 1 1
11265 M 2 B 3.2 4 8 12 NP . ˉ N N H 1 1
11267 M 2.2 B 3.2 4 8 12 NP . ˉ N N H 1 1
11269 M 4 B 3.2 4 7 11 NP . ˉ N N H 1 4
11274 M 4.1 B 3.2 4 7 11 NP . ˉ N N H 1 4
11283 M 3 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
11293 M 3.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
11295 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
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11296 M 3 O 1.6 3.8 7.6 8.7 NP . ˉ N L H 2 3
11298 M 3.2 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
11300 M 3.2 O 1.9 4.1 9.3 9.1 NP . ˉ N L H 2 3
11303 M 3.1 O 2 4.2 8.4 9.2 NP . ˉ L N 2 3
11305 M 3.1 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 3
11306 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 3
11309 M 3 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 3
11310 M 2.5 A 2.2 5.3 6 10 NP . ˉ N N H 1 2
11314 M 2.6 A 2.2 5.3 7 11 NP . ˉ N N H 1 2
11316 M 2.7 A 2.2 5.3 8 12 NP . ˉ N N H 1 2
11318 M 2.5 A 2.2 5.3 6 10 NP . ˉ N N H 1 2
11322 M 2.6 A 2.2 5.3 7 11 NP . ˉ N N H 1 2
11325 M 2.7 A 2.2 6.7 8 12 NP . ˉ N L H 1 2
11328 M 2.5 A 2.2 6.7 9 13 NP . ˉ 7% N L H 1 2
11330 M 2.6 A 2.2 6.7 9 13 NP . ˉ N L H 1 2
11335 M 2.7 A 2.2 6.7 8 12 NP . ˉ N L H 1 2
11337 M 2.5 A 2.2 6.7 9 13 NP . ˉ 6% N L H 1 2
11338 M 2 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 1
11339 M 2.2 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 1
11343 M 2.1 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 1
11346 M 2 O 1.6 3.8 8.6 8.8 NP . ˉ N N H 2 1
11348 M 2.2 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 1
11401 M 2.1 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 1
11353 M 2 O 2 4.2 9.3 9.2 NP . ˉ N N H 2 1
11356 M 2.1 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 1
11358 M 2.2 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 1
11367 M 2 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 1
11365 M 2.5 B 2.4 5.6 8 12 NP . ˉ N N H 1 2
11368 M 2.6 B 3.4 5.6 8 12 NP . ˉ N N H 1 2
11370 M 2.7 B 3.4 5.6 8 11 NP . ˉ N N H 1 2
11373 M 2.5 B 3.4 5.6 9 13 NP . ˉ N N H 1 2
11375 M 2.6 B 3.4 5.6 9 12 NP . ˉ N N H 1 2
11378 M 2.7 B 3.4 6.4 9 13 NP . ˉ N L H 1 2
11380 M 2.5 B 3.4 6.4 9 11 NP . ˉ N L H 1 2
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11383 M 2.6 B 3.4 6.4 10 15 P 3 1 dct+ 6% N AB H 1 2
11385 M 2.7 B 3.4 6.4 11 14 NP . ˉ N L H 1 2
11389 M 2.5 B 3.4 6.4 14 16 P 2 1 dct+ 6% N L H 1 2
11398 M 2 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 1
11402 M 2.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 1
11407 M 2.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 1
11409 M 2 O 1.6 3.8 8.8 8.8 NP . ˉ N L H 2 1
11415 M 2.2 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 1
11534 M 2.1 O 1.9 4.1 9.3 9.1 NP . ˉ N L H 2 1
11420 M 2 O 2 4.2 8.4 9.2 NP . ˉ L N 2 1
11430 M 2 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 1
11506 M 2 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 1
11607 M 2.1 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 1
11709 M 2.5 A 3.5 5.7 9 13 NP . ˉ N L H 1 2
12638 M 2.6 B 3.5 5.7 9 13 NP . ˉ N L H 1 2
12662 M 2.7 A 3.5 5.7 9 13 NP . ˉ N L H 1 2
12674 M 2.5 B 3.5 5.7 8 12 NP . ˉ N L H 1 2
12685 M 2.6 A 2.1 6 8 12 NP . ˉ N L H 1 2
12697 M 2.7 A 2.1 6.3 8 12 NP . ˉ N L H 1 2
12700 M 2.5 B 2.1 6.3 9 13 NP . ˉ N N H 1 2
12635 M 2.6 A 2.1 6.3 9 13 NP . ˉ N N H 1 2
12465 M 2.7 A 2.8 6.3 9 10 NP . ˉ N N H 1 2
12730 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
12746 M 3 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 3
12748 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 3
12751 M 3.1 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
12761 M 3.2 O 1.7 3.9 8.8 8.9 NP . ˉ N N H 2 3
12784 M 3.2 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 3
12783 M 3 O 2 4.2 8.4 9.2 NP . ˉ N N 2 3
12790 M 3 O 2.1 4.3 8.9 9.3 NP . ˉ N N H 2 3
12795 M 3.1 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
12794 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 3
12785 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
12745 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
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12865 M 2.7 O 1.5 3.7 8.5 8.7 NP . ˉ N L H 2 2
12863 M 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
12635 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
12874 M 2.5 O 1.8 4.1 8.3 9.1 NP . ˉ L N 2 2
12882 M 2.5 O 1.9 4.2 8.4 9.2 NP . ˉ L N 2 2
12889 M 2.6 O 2 4.3 8.5 9.3 NP . ˉ L N 2 2
12893 M 2.5 O 2.1 4.5 8.6 9.4 NP . ˉ L N 2 2
12897 M 2.6 O 2.2 3.5 8.7 9.5 NP . ˉ L N 2 2
12900 M 2.5 O 2.3 3.6 7.3 8.5 NP . ˉ N N 2 2
12904 M 2.6 O 1.3 3.7 7.4 8.6 NP . ˉ N N 2 2
12908 M 2.5 O 1.4 3.8 7.5 8.7 NP . ˉ N N 2 2
12915 M 2.7 O 1.5 3.9 7.6 8.8 NP . ˉ N N 2 2
12918 M 2.6 O 1.6 4.1 7.7 8.9 NP . ˉ N N 2 2
12924 M 2.7 O 1.7 4.2 8.3 9.1 NP . ˉ N N 2 2
12928 M 2.6 O 1.9 4.3 8.4 9.2 NP . ˉ N N 2 2
12840 M 2.5 O 2 4.4 8.5 9.3 NP . ˉ N N 2 2
12859 M 2.6 O 2.1 4.5 8.6 9.4 NP . ˉ N N 2 2
12968 M 2.5 O 2.2 4 8 9 NP . ˉ N N 2 2
12875 M 2.6 O 2.3 4.5 7.3 9.5 NP . ˉ L N 2 2
12883 M 2.5 O 1.3 3.5 7.4 8.5 NP . ˉ L N 2 2
12986 M 2.6 O 1.4 3.6 7.5 8.6 NP . ˉ L N 2 2
12892 M 2.5 O 1.5 3.7 7.6 8.7 NP . ˉ L N 2 2
12896 M 2.6 O 1.6 3.8 7.7 8.8 NP . ˉ L N 2 2
12999 M 2.7 O 1.7 3.9 8.3 8.9 NP . ˉ L N 2 2
13007 M 2.7 O 1.9 4.1 8.4 9.1 NP . ˉ L N 2 2
13010 M 2.6 O 2 4.2 8.5 9.2 NP . ˉ L N 2 2
13017 M 2.5 O 2.1 4.3 8.6 9.3 NP . ˉ L N 2 2
13016 M 2.7 O 2.2 4.4 8.7 9.4 NP . ˉ L N 2 2
13025 M 2.5 O 2.3 4.5 7.3 9.5 NP . ˉ N N 2 2
13027 M 2.6 O 1.3 3.5 7.4 8.5 NP . ˉ N N 2 2
13032 M 2.7 O 1.4 3.6 7.5 8.6 NP . ˉ N N 2 2
13040 M 2.6 O 1.5 3.7 7.6 8.7 NP . ˉ N N 2 2
13048 M 2.5 O 1.6 3.8 7.7 8.8 NP . ˉ N N 2 2
13056 M 2.6 O 1.7 3.9 8.3 8.9 NP . ˉ N N 2 2
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13062 M 2.5 O 1.9 4.1 8.4 9.1 NP . ˉ N N 2 2
13073 M 2.5 O 2 4.2 8.5 9.2 NP . ˉ N N 2 2
13083 M 2.6 O 2.1 4.3 8.6 9.3 NP . ˉ N N 2 2
13095 M 2.5 O 2.2 4.4 8.7 9.4 NP . ˉ N N 2 2
13116 M 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
13124 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
13137 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
13144 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
13147 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
13256 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
13278 M 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
13298 M 2.6 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
13318 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
13325 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
13328 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
13337 M 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
13343 M 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
13348 M 2.7 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
13356 M 2.7 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
13359 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
13363 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
13367 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
13373 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
13376 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
13379 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
13383 M 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
13394 M 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
13404 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
13413 M 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
13427 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
13468 M 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
13484 M 2.6 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
13492 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
13567 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
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13578 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
13583 M 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
13593 M 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
13610 M 2.7 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
13627 M 2.7 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
13635 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
13637 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
13640 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
13642 M 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
13647 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
13653 M 2.1 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 1
13660 M 2.2 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 1
13664 M 2.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 1
13666 M 2.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 1
13669 M 2 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 1
13673 M 2.2 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 1
13675 M 2.2 O 2.3 4.1 8.3 9.1 NP . ˉ L N 2 1
13679 M 2 O 1.9 4.2 8.4 9.2 NP . ˉ L N 2 1
13682 M 2.1 O 2 4.3 8.5 9.3 NP . ˉ L N 2 1
13685 M 2.5 O 2.1 4.4 8.6 9.4 NP . ˉ L N 2 2
13689 M 2.5 O 2.2 4.5 8.7 9.5 NP . ˉ N N 2 2
13693 M 2.6 O 2.3 3.5 7.3 8.5 NP . ˉ N N 2 2
13699 M 2.6 O 1.3 3.6 7.4 8.6 NP . ˉ N N 2 2
13702 M 2.6 O 1.4 3.7 7.5 8.7 NP . ˉ N N 2 2
13704 M 2.6 O 1.5 3.8 7.6 8.8 NP . ˉ N N 2 2
13707 M 2.6 O 1.6 3.9 7.7 8.9 NP . ˉ N N 2 2
13712 M 2.5 O 1.7 4.1 8.3 9.1 NP . ˉ N N 2 2
13714 M 2.5 O 1.9 4.2 8.4 9.2 NP . ˉ N N 2 2
13718 M 2.6 O 2 4.3 8.5 9.3 NP . ˉ N N 2 2
13722 M 2.1 O 2.1 4.4 8.6 9.4 NP . ˉ N N 2 1
13724 M 2.2 O 2.2 4.5 8.7 9.5 NP . ˉ N N 2 1
13729 M 2 O 2.3 4 8 9 NP . ˉ L N 2 1
13732 M 2 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 1
13738 M 2 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 1
114
13741 M 2.2 O 1.5 3.7 7.5 8.78 NP . ˉ L N 2 1
13743 M 2 O 1.6 3.8 7.6 0.8 NP . ˉ L N 2 1
13747 M 2.1 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 1
13750 M 2 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 1
13752 M 2.1 O 2 4.2 8.4 9.2 NP . ˉ L N 2 1
13758 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
13761 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
13772 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
13777 M 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
13778 M 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
13779 M 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
13782 M 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
13785 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
13787 M 2.7 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
13789 M 2.7 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
13792 M 2.7 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
13795 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
13799 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
13800 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
13802 M 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
13804 M 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
13806 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
13808 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
13806 M 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
13807 M 2.6 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
13809 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
13811 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
13814 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
13816 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
13817 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
13818 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
13819 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
13821 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
13822 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
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13824 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
13825 M 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
13826 M 2.7 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
13828 M 2.7 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
13832 M 2.7 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
13835 M 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
13836 M 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
13837 M 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
13838 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
13842 M 2.7 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
13843 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
13845 M 2 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 1
13846 M 2.1 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 1
13847 M 2 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 1
13849 M 2 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 1
13851 M 2 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 1
13856 M 2.1 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 1
13859 M 2.2 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 1
13857 M 2 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 1
13858 M 2.1 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 1
13860 M 2 O 2 4.2 8.4 9.2 NP . ˉ N N 2 1
13862 M 2.9 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 3
13864 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
13865 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 3
13867 M 3.2 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 3
13868 M 3.2 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 3
13869 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 3
13871 M 3.1 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
13872 M 3.1 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 3
13875 M 3 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 3
13876 M 3.1 O 2 4.2 8.4 9.2 NP . ˉ N N 2 3
13878 M 3.2 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 3
13881 M 3.1 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
13882 M 3.2 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 3
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13884 M 3 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
13885 M 3.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
13885 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
13887 M 3 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 3
13889 M 3.1 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
13891 M 3.1 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 3
13892 M 3 O 2 4.2 8.4 9.2 NP . ˉ L N 2 3
13894 M 3 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 3
13895 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 3
13895 M 3 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 3
13896 M 3 O 2.3 4.4 7.3 9.5 NP . ˉ L N 2 3
13897 M 3 O 2.2 4.3 7.4 9.4 NP . ˉ L N 2 3
13900 M 3.1 O 2.1 4.2 7.5 9.3 NP . ˉ L N 2 3
13902 M 3.1 O 2 4.1 7.6 9.2 NP . ˉ L N 2 3
13904 M 3.2 O 1.9 3.9 7.7 9.1 NP . ˉ L N 2 3
13905 M 3 O 1.7 4.5 8.3 8.9 NP . ˉ L N 2 3
13907 M 3 O 1.6 3.8 8.4 8.8 NP . ˉ L N 2 3
13910 M 3.2 O 1.5 3.7 8.5 8.7 NP . ˉ L N 2 3
13914 M 3.1 O 1.4 3.6 8.6 8.6 NP . ˉ L N 2 3
13916 M 3.2 O 1.3 3.5 8.7 8.5 NP . ˉ L N 2 3
13919 M 3.1 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 3
13923 M 3.2 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 3
13926 M 3.1 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 3
13929 M 3.2 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
13931 M 3 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 3
13933 M 3.1 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 3
13935 M 3.2 O 2 4.2 8.4 9.2 NP . ˉ N N 2 3
13937 M 3 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 3
13939 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
13941 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 3
13942 M 3.2 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 3
13944 M 3 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 3
13947 M 3.1 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 3
13950 M 3.2 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
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13964 M 3.1 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 3
13967 M 3.2 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 3
13969 M 3.1 O 2 4.2 8.4 9.2 NP . ˉ N N 2 3
13972 M 3.2 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 3
13975 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
13976 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 3
13979 M 3 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
13981 M 3.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
13984 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
13986 M 3.1 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 3
13988 M 3.2 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
13989 M 3.2 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 3
13992 M 3.1 O 2 4.2 8.4 9.2 NP . ˉ L N 2 3
13995 M 3.2 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 3
13999 M 3.2 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 3
14003 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 3
14006 M 3 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
14008 M 3.2 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
14010 M 3.1 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
14014 M 3.2 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 3
14016 M 3.1 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
14017 M 3.2 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 3
14018 M 3.1 O 2 4.2 8.4 9.2 NP . ˉ L N 2 3
14020 M 3.2 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 3
14024 M 3.2 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 3
14025 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 3
14026 M 3.2 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 3
14027 M 3.1 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 3
14029 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 3
14030 M 3.1 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
14032 M 3 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 3
14033 M 3 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 3
14036 M 3 O 2 4.2 8.4 9.2 NP . ˉ N N 2 3
14038 M 3 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 3
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14039 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
14041 M 3.2 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 3
14043 M 3.1 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 3
14045 M 3.2 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 3
14046 M 3.1 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 3
14047 M 3.2 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
14048 M 3 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 3
14049 M 3 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 3
14051 M 3.2 O 2 4.2 8.4 9.2 NP . ˉ N N 2 3
14053 M 3.2 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 3
14055 M 3 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 3
14056 M 3.1 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 3
14057 M 3.2 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
14059 M 3.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
14061 M 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
14063 M 3.2 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 3
14063 M 3.1 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
14065 M 3 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 3
14067 M 3.1 O 2 4.2 8.4 9.2 NP . ˉ L N 2 3
14069 M 3.2 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 3
14071 M 3.2 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 3
14072 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
14075 M 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
14076 M 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
14079 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
14082 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
14085 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
14087 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
14089 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
14111 M 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
14113 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
14115 M 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
14116 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
14119 M 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
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14117 M 2.7 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
14118 M 2.7 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
14114 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
14120 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
14123 M 2.6 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
14125 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
14126 M 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
14128 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
14131 M 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
14132 M 2.5 O 1.4 3.6 7.47 8.6 NP . ˉ N N 2 2
14135 M 2.6 O 1.5 3.7 0.5 8.7 NP . ˉ N N 2 2
14137 M 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
14139 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
14141 M 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
14142 M 2.7 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
14143 M 2.7 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
14145 M 2.7 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
14148 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
14149 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
14151 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
14153 M 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
14157 M 2.5 O 1.6 3.8 7.6 8.7 NP . ˉ L N 2 2
14158 M 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
14162 M 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
14167 M 2.6 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
14168 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
14169 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
14172 M 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
14174 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
14176 M 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
14177 M 2.7 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
14178 M 2.7 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
14179 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
14182 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
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14183 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
14185 M 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
14186 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
14188 M 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
14189 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
14191 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
14192 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
14193 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
14195 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
14196 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
14197 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
14199 M 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
14198 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
14200 M 2.7 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
14202 M 2.7 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
14208 M 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
14209 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
14212 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
14214 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
14216 M 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
14218 M 2.5 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
14220 M 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
14222 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
14226 M 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
14228 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
14231 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
14233 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
14234 M 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
14236 M 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
14238 M 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
14240 M 2.6 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
14242 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
14245 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
14247 M 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
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14249 M 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
14250 M 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
14255 M 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
14257 M 2.7 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
14259 M 2.7 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
14261 M 2.7 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
14263 M 2.7 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
14265 M 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
14266 M 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
14269 M 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
14270 F 2.9 A 2.4 5.1 8 12 NP . ˉ N L H 1 3
14272 F 3.1 A 2.4 5.1 9 13 NP . ˉ N N H 1 3
14275 F 3.2 A 2.4 5.1 9 13 NP . ˉ N N H 1 3
14277 F 2.9 A 2.4 5.1 9 12 NP . ˉ N N H 1 3
14279 F 2.9 A 2.4 5.1 8 12 NP . ˉ N N H 1 3
14281 F 3.1 A 3.2 6.9 9 13 NP . ˉ N L H 1 3
14283 F 3.1 A 3.2 6.9 9 11 NP . ˉ N L H 1 3
14285 F 3.2 A 3.2 6.9 10 15 P 3 1 dct+ 6% N L H 1 3
14287 F 3.2 A 3.2 6.9 11 14 NP . ˉ N AB H 1 3
14289 F 2.5 A 3.2 6.9 14 16 P 2 2 dct+ 8% S+ L H 1 2
14290 F 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
14293 F 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
14295 F 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
14297 F 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
14299 F 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
14310 F 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
14314 F 2.5 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
14317 F 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
14319 F 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
14320 F 2.6 O 2.3 4.4 8.7 9.5 NP . ˉ N N 2 2
14322 F 3.1 B 2.3 4 7 11 NP . ˉ N N H 1 3
14324 F 3.1 B 2.3 4 7 11 NP . ˉ N N H 1 3
14325 F 3.1 B 2.3 5.9 9 13 NP . ˉ N N H 1 3
14327 F 3.2 B 2.3 4 8 12 NP . ˉ N N H 1 3
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14329 F 3.2 B 2.3 4 8 12 NP . ˉ N N H 1 3
14331 F 3.2 B 3.3 6.1 11.5 11 P 2 1 dct+ 6% N L H 1 3
14335 F 2.9 B 3.3 5 8.5 15 NP . ˉ N AB H 1 3
14339 F 2.9 B 3.3 11 10 14 P 1 2 dct+ 8% S+ L H 1 3
14340 F 2.9 B 3.3 4 8 12 NP . ˉ N L H 1 3
3 F 2 B 3.4 12 14 16 P 1 2 21 done dct+ 7% S+ L H 1 3
5 F 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
7 F 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
8 F 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
6 F 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
9 F 2.7 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
10 F 2.7 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
11 F 2.7 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
13 F 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
15 F 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
16 F 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
17 F 2.5 A 2.5 4 8 12 NP . ˉ N L H 1 2
19 F 2.9 A 2.5 4 8 12 NP . ˉ N L H 1 3
21 F 2.9 A 2.5 5.3 9 13 NP . ˉ NN L H 1 3
23 F 3.1 A 2.5 5.3 9 13 NP . ˉ N L H 1 3
24 F 3.1 A 2.5 5.3 9 13 NP . ˉ N L H 1 3
25 F 3.1 A 3.1 6.7 9 13 NP . ˉ N N H 1 3
27 F 3.2 A 3.1 6.7 9 13 NP . ˉ N N H 1 3
29 F 3.2 B 3.1 6.7 9 12 NP . ˉ N N H 1 3
30 F 3.2 B 3.1 5 8 12 NP . ˉ N AB H 1 3
32 F 3.1 B 3.1 11 12 16 P 1 2 dct+ 8% S+ N H 1 3
33 F 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
35 F 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
37 F 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
39 F 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
41 F 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
43 F 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ AB N 2 2
45 F 2.5 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
47 F 2.7 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
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49 F 2.7 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
50 F 2.7 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
51 F 2.5 A 2.8 5.4 7 11 NP . ˉ N L H 1 2
52 F 2.6 AB 2.8 5.4 9 13 NP . ˉ N L H 1 2
54 F 2.5 AB 2.8 6.6 8 11 NP . ˉ N N H 1 2
56 F 2.6 A 2.8 6.6 9 13 NP . ˉ N N H 1 2
58 F 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
59 F 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
61 F 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
62 F 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
64 F 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ N N 2 2
68 F 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
69 F 2.6 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
71 F 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
72 F 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
73 F 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
74 F 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
76 F 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
78 F 2.6 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
79 F 2.5 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
80 F 2.6 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
83 F 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
84 F 2.5 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
85 F 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
86 F 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
89 F 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
91 F 2.6 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 2
93 F 2.5 O 1.4 3.6 7.4 8.6 NP . ˉ AB N 2 2
95 F 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
96 F 2.6 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 2
97 F 2.5 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
98 F 2.6 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 2
101 F 2.5 O 2 4.2 8.4 9.2 NP . ˉ L N 2 2
103 F 2.6 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 2
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105 F 2.5 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 2
106 F 2.6 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 2
107 F 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 2
109 F 2.7 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 2
111 F 2.7 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 2
112 F 2.7 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 2
113 F 2.7 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 2
116 F 2.5 O 1.9 4.1 8.3 9.1 NP . ˉ N N 2 2
120 F 2.6 O 2 4.2 8.4 9.2 NP . ˉ N N 2 2
124 F 2.5 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 2
128 F 2.6 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 2
131 F 2.5 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 2
135 F 2.5 O 1.3 3.5 7.3 8.5 NP . ˉ AB N 2 2
145 F 2.6 O 1.4 3.6 7.4 8.6 NP . ˉ N N 2 2
149 F 2.5 O 1.5 3.7 7.5 8.7 NP . ˉ N N 2 2
158 F 3 O 1.6 3.8 7.6 8.8 NP . ˉ N N 2 3
165 F 3.1 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
168 F 3.2 O 1.9 4.1 8.3 9.1 NP . ˉ L N 2 3
175 F 3.1 O 2 4.2 8.4 9.2 NP . ˉ L N 2 3
179 F 3 O 2.1 4.3 8.5 9.3 NP . ˉ L N 2 3
185 F 3.2 O 2.2 4.4 8.6 9.4 NP . ˉ L N 2 3
189 F 3.2 O 2.3 4.5 8.7 9.5 NP . ˉ L N 2 3
195 F 3.1 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
201 F 3.2 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
245 F 3.1 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
256 F 3.2 O 1.8 3.8 7.6 8.8 NP . ˉ L N 2 3
265 F 3.2 O 2.1 3.9 7.7 8.9 NP . ˉ N N 2 3
276 F 3.2 O 2.2 4.1 8.3 9.1 NP . ˉ N N 2 3
284 F 3.2 O 2.3 4.2 8.4 9.2 NP . ˉ N N 2 3
296 F 3.2 O 1.3 4.3 8.5 9.3 NP . ˉ N N 2 3
301 F 3.1 O 1.4 4.4 8.6 9.4 NP . ˉ N N 2 3
318 F 3.2 O 1.5 4.5 8.7 9.5 NP . ˉ N N 2 3
329 F 3.2 O 1.6 3.5 7.3 8.5 NP . ˉ N N 2 3
334 F 3.2 O 1.7 3.6 7.4 8.6 NP . ˉ N N 2 3
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349 F 3.2 O 1.8 4 8 9 NP . ˉ N N 2 3
357 F 3.1 O 1.9 3.7 7.5 8.7 NP . ˉ N N 2 3
368 F 3.1 O 2 4.3 8.5 9.3 NP . ˉ AB N 2 3
374 F 3.1 O 2.1 4.4 8.6 9.4 NP . ˉ L N 2 3
384 F 3 O 2.2 4.5 8.7 9.5 NP . ˉ L N 2 3
394 F 3 O 2.3 4 8 9 NP . ˉ L N 2 3
401 F 3 O 1.3 3.5 7.3 8.5 NP . ˉ L N 2 3
416 F 3.1 O 1.4 3.6 7.4 8.6 NP . ˉ L N 2 3
586 F 3.2 O 1.5 3.7 7.5 8.7 NP . ˉ L N 2 3
694 F 3.1 O 1.6 3.8 7.6 8.8 NP . ˉ L N 2 3
787 F 3 O 1.7 3.9 7.7 8.9 NP . ˉ L N 2 3
894 F 2 O 1.8 4.1 8.3 9.1 NP . ˉ L N 2 1
999 F 2.1 O 1.9 4.2 8.4 9.2 NP . ˉ L N 2 1
1091 F 2.1 O 2.1 4.3 8.5 9.3 NP . ˉ N N 2 1
1152 F 2 O 2.2 4.4 8.6 9.4 NP . ˉ N N 2 1
1247 F 2.2 O 2.3 4.5 8.7 9.5 NP . ˉ N N 2 1
1482 F 2 O 1.3 3.5 7.3 8.5 NP . ˉ N N 2 1
1698 F 2 B 1.4 3.6 7.4 8.6 NP . ˉ N N 1 1
1762 F 2.2 B 1.5 3.7 7.5 8.7 NP . ˉ N N 1 1
1985 F 2 B 1.6 3.8 7.6 8.8 NP . ˉ N N 1 1
2165 F 2 B 1.7 3.9 7.7 8.9 NP . ˉ N N 1 1
2354 F 3.4 B 1.8 4 8 9 NP . ˉ N N 1 4
2468 F 3.5 B 1.9 4.1 8.3 9.5 NP . ˉ N N 1 4
2568 F 3.6 B 2 4.2 8.4 9.1 NP . ˉ L N 1 4
2589 F 3 B 2.1 4.3 8.5 9.2 NP . ˉ L N 1 3
2785 F 3.7 B 2.2 4.4 8.6 9.3 NP . ˉ L N 1 4
2791 F 4 B 2.3 4.5 8.7 9.4 NP . ˉ L N 1 4
2798 F 3.5 B 1.3 3.5 7.3 8.5 NP . ˉ L N 1 4
2831 F 3.6 B 1.4 3.6 7.4 8.6 NP . ˉ L N 1 4
2851 F 3.9 B 1.5 3.7 7.5 8.7 NP . ˉ L N 1 4
2894 F 35 B 1.6 3.8 7.6 8.8 NP . ˉ L N 1 4
2914 F 2.5 B 1.7 3.9 7.7 8.9 NP . ˉ L N 1 2
2935 F 2.6 B 1.8 4 8 9 NP . ˉ N N 1 2
2975 F 2.5 B 1.9 4.1 8.3 9.1 NP . ˉ N N 1 2
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2999 F 2.6 B 2 4.2 8.4 9.2 NP . ˉ N N 1 2
3016 F 2.7 B 2.1 4.3 8.5 9.3 NP . ˉ N N 1 2
3056 F 2.7 B 2.2 4.4 8.6 9.4 NP . ˉ N N 1 2
3089 F 2.7 B 2.3 4.5 8.7 9.5 NP . ˉ N N 1 2
3126 F 2.7 B 1.3 3.5 7.3 8.5 NP . ˉ N N 1 2
3148 F 2.7 B 1.4 3.6 7.4 8.6 NP . ˉ N N 1 2
3179 F 2.5 B 1.5 3.7 7.5 8.7 NP . ˉ N N 1 2
3245 F 2.6 B 1.6 3.8 7.6 8.8 NP . ˉ N N 1 2
3289 F 2.6 B 1.7 3.9 7.7 8.9 NP . ˉ N N 1 2
3352 F 2.6 B 1.8 4 8 9 NP . ˉ L N 1 2
3457 F 2.6 B 1.9 4.1 8.3 9.1 NP . ˉ L N 1 2
3564 F 2.6 B 2 4.2 8.4 9.2 NP . ˉ L N 1 2
3624 F 2.6 B 2.1 4.3 8.5 9.3 NP . ˉ L N 1 2
3789 F 2.6 B 2.2 4.4 8.6 9.4 NP . ˉ AB N 1 2
3841 F 2.5 B 2.3 4.5 8.7 9.5 NP . ˉ L N 1 2
3962 F 2.5 B 1.3 3.5 7.3 8.5 NP . ˉ L N 1 2
4035 F 2.5 B 1.4 3.6 7.4 8.6 NP . ˉ L N 1 2
4132 F 2.5 B 1.5 3.7 7.5 8.7 NP . ˉ L N 1 2
4265 F 2.5 B 1.6 3.8 7.6 8.8 NP . ˉ L N 1 2
4351 F 2.5 B 1.7 3.9 7.7 8.9 NP . ˉ L N 1 2
4451 F 2.6 B 1.8 4 8 9 NP . ˉ L N 1 2
4512 F 2.6 B 1.9 4.1 8.3 9.1 NP . ˉ L N 1 2
4621 F 2.6 B 2 4.2 8.4 9.2 NP . ˉ L N 1 2
4785 F 2.5 B 2.1 4.3 8.5 9.3 NP . ˉ L N 1 2
4857 F 2.5 B 2.2 4.4 8.6 9.4 NP . ˉ L N 1 2
4987 F 2.5 B 2.3 4.5 8.7 9.5 NP . ˉ L N 1 2
5246 F 2.5 B 1.3 3.5 7.3 8.5 NP . ˉ L N 1 2
5468 F 2.5 B 1.4 3.6 7.4 8.6 NP . ˉ L N 1 2
5698 F 2.5 B 1.5 3.7 7.5 8.7 NP . ˉ N N 1 2
5862 F 2.6 B 1.6 3.8 7.6 8.8 NP . ˉ N N 1 2
6143 F 2.6 B 1.7 3.9 7.7 8.9 NP . ˉ N N 1 2
6354 F 2.6 B 1.8 4 8 9 NP . ˉ N N 1 2
6345 F 2.6 B 1.9 4.1 8.3 9.1 NP . ˉ N N 1 2
6478 F 2.5 B 2 4.2 8.4 9.2 NP . ˉ N N 1 2
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6524 F 2.5 B 2.1 4.3 8.5 9.3 NP . ˉ N N 1 2
6621 F 2.5 B 2.2 4.4 8.6 9.4 NP . ˉ N N 1 2
6789 F 2.6 B 2.3 4.5 8.7 9.5 NP . ˉ N N 1 2
6842 F 2.5 B 1.3 3.5 7.3 8.5 NP . ˉ N N 1 2
6954 F 2.6 B 1.4 3.6 7.4 8.6 NP . ˉ N N 1 2
7012 F 2.5 B 1.5 3.7 7.5 8.7 NP . ˉ N N 1 2
7034 F 2.6 B 1.6 3.8 7.6 8.8 NP . ˉ N N 1 2
7064 F 3 B 1.7 3.9 7.7 8.9 NP . ˉ N N 1 3
7089 F 3.2 B 1.8 4 8 9 NP . ˉ N N 1 3
7215 F 3.1 B 1.9 4.1 8.3 9.1 NP . ˉ N N 1 3
7354 F 3.2 B 2 4.2 8.4 9.2 NP . ˉ N N 1 3
7267 F 3.1 B 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
7389 F 3 B 2.2 4.4 8.6 9.4 NP . ˉ N N 1 3
7359 F 3.1 B 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
7489 F 3.2 B 1.3 3.5 7.3 8.5 NP . ˉ L N 1 3
7491 F 3.1 B 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
7513 F 3.2 B 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
7548 F 3.2 B 1.6 3.8 7.6 8.8 NP . ˉ L N 1 3
7684 F 3.1 B 1.7 3.9 7.7 8.9 NP . ˉ L N 1 3
7789 F 3.2 B 1.8 4 8 9 NP . ˉ L N 1 3
7894 F 3.1 B 1.9 4.1 8.3 9.1 NP . ˉ L N 1 3
7921 F 3.1 B 2 4.2 8.4 9.2 NP . ˉ L N 1 3
8123 F 3.1 B 2.1 4.3 8.5 9.3 NP . ˉ L N 1 3
8236 F 3.1 B 2.2 4.4 8.6 9.4 NP . ˉ L N 1 3
8345 F 3 B 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
8465 F 3.2 B 1.3 3.5 7.3 8.5 NP . ˉ N N 1 3
8513 F 3 B 1.4 3.6 7.4 8.6 NP . ˉ N N 1 3
8624 F 3 B 1.5 3.7 7.5 8.7 NP . ˉ N N 1 3
8792 F 3 B 1.6 3.8 7.6 8.8 NP . ˉ N N 1 3
8813 F 3 B 1.7 3.9 7.7 8.9 NP . ˉ N N 1 3
8954 F 3 B 1.8 4 8 9 NP . ˉ N N 1 3
9014 F 3 B 1.9 4.1 8.3 9.1 NP . ˉ N N 1 3
9023 F 3.1 B 2 4.2 8.4 9.2 NP . ˉ N N 1 3
9046 F 3.1 B 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
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9056 F 3.2 B 2.2 4.4 8.6 9.4 NP . ˉ N N 1 3
9075 F 3.2 B 2.3 4.5 8.7 9.5 NP . ˉ L N 1 3
9078 F 3.1 B 1.3 3.5 7.3 8.5 NP . ˉ L N 1 3
9081 F 3.2 B 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
9086 F 3.1 B 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
9090 F 3.2 B 1.6 3.8 7.6 8.8 NP . ˉ AB N 1 3
9098 F 3.2 B 1.7 3.9 7.7 8.9 NP . ˉ L N 1 3
9123 F 3.1 B 1.9 4.1 8.3 9.1 NP . ˉ L N 1 3
9145 F 3.2 B 2 4.2 8.4 9.2 NP . ˉ L N 1 3
9178 F 3.6 B 2.1 4.3 8.5 9.3 NP . ˉ L N 1 4
9189 F 3.5 B 2.2 4.4 8.6 9.4 NP . ˉ L N 1 4
9347 F 3.8 B 2.3 4.5 8.7 9.5 NP . ˉ L N 1 4
9357 F 3.6 B 1.3 3.5 7.3 8.5 NP . ˉ N N 1 4
9367 F 3.9 B 1.4 3.6 7.4 8.6 NP . ˉ N N 1 4
9384 F 4 B 1.5 3.7 7.5 8.7 NP . ˉ N N 1 4
9391 F 3.7 B 1.6 3.8 7.6 8.8 NP . ˉ N N 1 4
9412 F 3.6 B 1.7 3.9 7.7 8.9 NP . ˉ N N 1 4
9435 F 3.6 B 1.9 4.1 8.3 9.1 NP . ˉ N N 1 4
9456 F 3.6 B 2 4.2 8.4 9.2 NP . ˉ N N 1 4
9467 F 3.6 B 2.1 4.3 8.5 9.3 NP . ˉ N N 1 4
9478 F 3.5 B 2.2 4.4 8.6 9.4 NP . ˉ N N 1 4
9489 F 3 B 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
9491 F 3 B 1.3 3.5 7.3 8.5 NP . ˉ N N 1 3
9499 F 3 A 1.4 3.6 7.4 8.6 NP . ˉ N N 1 3
9511 F 3 A 1.5 3.7 7.5 8.7 NP . ˉ N N 1 3
9521 F 3 A 1.6 3.8 7.6 8.8 NP . ˉ N N 1 3
9524 F 3.1 A 1.7 3.9 7.7 8.9 NP . ˉ N N 1 3
9526 F 3 A 1.9 4.1 8.3 9.1 NP . ˉ N N 1 3
9567 F 3 A 2 4.2 8.4 9.2 NP . ˉ N N 1 3
9578 F 3 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
9589 F 3 A 2.2 4.4 8.6 9.4 NP . ˉ N N 1 3
9591 F 3.1 A 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
9612 F 3 A 1.3 3.5 7.3 8.5 NP . ˉ N N 1 3
9623 F 3 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
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9634 F 3.2 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
9645 F 3 A 1.6 3.8 7.6 8.8 NP . ˉ N N 1 3
9656 F 3 A 1.7 3.9 7.7 8.9 NP . ˉ N N 1 3
9667 F 3 A 1.9 4.1 8.3 9.1 NP . ˉ N N 1 3
9678 F 3 A 2 4.2 8.4 9.2 NP . ˉ N N 1 3
9689 F 3 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
9692 F 2.5 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 2
9712 F 2.6 A 2.3 4.5 8.7 9.5 NP . ˉ L N 1 2
9718 F 2.5 A 1.3 3.5 7.3 8.5 NP . ˉ L N 1 2
9719 F 2.6 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 2
9721 F 2.5 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 2
9724 F 2.6 A 1.6 3.8 7.6 8.8 NP . ˉ L N 1 2
9726 F 2.5 A 1.7 3.9 7.7 8.9 NP . ˉ L N 1 2
9777 F 2.6 A 1.9 4.1 8.3 9.1 NP . ˉ L N 1 2
9789 F 2.5 A 2 4.2 8.4 9.2 NP . ˉ L N 1 2
9791 F 2.7 A 2.1 4.3 8.5 9.3 NP . ˉ L N 1 2
9799 F 2.6 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 2
9841 F 2.5 A 2.3 4.5 8.7 9.5 NP . ˉ L N 1 2
9851 F 2.6 A 1.3 3.5 7.3 8.5 NP . ˉ L N 1 2
9854 F 2.6 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 2
9857 F 2.7 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 2
9876 F 2.5 A 1.6 3.8 7.6 8.8 NP . ˉ L N 1 2
9879 F 2.6 A 1.7 3.9 7.7 8.9 NP . ˉ L N 1 2
9888 F 2.5 A 1.9 4.1 8.3 9.1 NP . ˉ L N 1 2
9891 F 2.6 A 2 4.2 8.4 9.2 NP . ˉ L N 1 2
9912 F 2.7 A 2.1 4.3 8.5 9.3 NP . ˉ L N 1 2
9975 F 2.9 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 3
9991 F 2.9 A 2.3 4.5 8.7 9.5 NP . ˉ L N 1 3
10121 F 2.9 A 1.3 3.5 7.3 8.5 NP . ˉ L N 1 3
10241 F 3 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
10246 F 3 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
10256 F 3 A 1.6 3.8 7.6 8.8 NP . ˉ L N 1 3
10267 F 3.1 A 1.7 3.9 7.7 8.9 NP . ˉ L N 1 3
10274 F 3.1 A 1.9 4.1 8.3 9.1 NP . ˉ L N 1 3
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10280 F 3.1 A 2 4.2 8.4 9.2 NP . ˉ L N 1 3
10291 F 3 A 2.1 4.3 8.5 9.3 NP . ˉ L N 1 3
10301 F 2.9 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 3
10312 F 2.9 A 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
10323 F 2.9 A 1.3 3.5 7.3 8.5 NP . ˉ N N 1 3
10334 F 3 A 1.4 3.6 7.4 8.6 NP . ˉ N N 1 3
10345 F 3 A 1.5 3.7 7.5 8.7 NP . ˉ N N 1 3
10356 F 3 A 1.6 3.8 7.6 8.8 NP . ˉ N N 1 3
10367 F 3.1 A 1.7 3.9 7.7 8.9 NP . ˉ N N 1 3
10378 F 3.1 A 1.9 4.1 8.3 9.1 NP . ˉ N N 1 3
10389 F 3.1 A 2 4.2 8.4 9.2 NP . ˉ N N 1 3
10397 F 3.1 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
10399 F 2.5 A 2.2 4.4 8.6 9.4 NP . ˉ N N 1 2
10401 F 2.6 A 2.3 4.5 8.7 9.5 NP . ˉ N N 1 2
10409 F 2.5 A 1.3 3.5 7.3 8.5 NP . ˉ N N 1 2
10411 F 2.7 A 1.4 3.6 7.4 8.6 NP . ˉ N N 1 2
10413 F 2.6 A 1.5 3.7 7.5 8.7 NP . ˉ N N 1 2
10415 F 2.6 A 1.6 3.8 7.6 8.8 NP . ˉ N N 1 2
10425 F 2.7 A 1.7 3.9 7.7 8.9 NP . ˉ N N 1 2
10434 F 2.6 A 1.9 4.1 8.3 9.1 NP . ˉ N N 1 2
10436 F 2.5 A 2 4.2 8.4 9.2 NP . ˉ N N 1 2
10438 F 2.6 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 2
10345 F 2.5 A 2.2 4.4 8.6 9.4 NP . ˉ N N 1 2
10439 F 2.6 A 2.3 4.5 8.7 9.5 NP . ˉ N N 1 2
10441 F 2.5 A 1.3 3.5 7.3 8.5 NP . ˉ N N 1 2
10443 F 2.7 A 1.4 3.6 7.4 8.6 NP . ˉ N N 1 2
10445 F 2.7 A 1.5 3.7 7.5 8.7 NP . ˉ N N 1 2
10447 F 2.5 A 1.6 3.8 7.6 8.8 NP . ˉ N N 1 2
10449 F 2.6 A 1.7 3.9 7.7 8.9 NP . ˉ N N 1 2
10450 F 2.5 A 1.9 4.1 8.3 9.1 NP . ˉ N N 1 2
10461 F 2.6 A 2 4.2 8.4 9.2 NP . ˉ N N 1 2
10463 F 2.5 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 2
10465 F 2.9 A 2.2 4.4 8.6 9.4 NP . ˉ N N 1 3
10467 F 3 A 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
10469 F 3.1 A 1.3 3.5 7.3 8.5 NP . ˉ L N 1 3
10471 F 3.2 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
10473 F 3 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
10475 F 3.2 A 1.6 3.8 7.6 8.8 NP . ˉ L N 1 3
10476 F 3.2 A 1.7 3.9 7.7 8.9 NP . ˉ L N 1 3
10477 F 3.1 A 1.9 4.1 8.3 9.1 NP . ˉ L N 1 3
10479 F 3 A 2 4.2 8.4 9.2 NP . ˉ L N 1 3
10480 F 3.1 A 2.1 4.3 8.5 9.3 NP . ˉ L N 1 3
10481 F 3.2 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 3
10482 F 3 A 2.3 4.5 8.7 9.5 NP . ˉ L N 1 3
10483 F 3 A 1.3 3.5 7.3 8.5 NP . ˉ L N 1 3
10484 F 3 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
10485 F 3.2 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
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10486 F 3 A 1.6 3.8 7.6 8.8 NP . ˉ L N 1 3
10489 F 3.1 A 1.7 3.9 7.7 8.9 NP . ˉ L N 1 3
10491 F 3 A 1.9 4.1 8.3 9.1 NP . ˉ L N 1 3
10492 F 3.1 A 2 4.2 8.4 9.2 NP . ˉ L N 1 3
10493 F 3.2 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
10494 F 3.1 A 2.2 4.4 8.6 9.4 NP . ˉ N N 1 3
10496 F 3.1 A 2.3 4.5 8.7 9.5 NP . ˉ N N 1 3
10497 F 3.2 A 1.3 3.5 7.3 8.5 NP . ˉ N N 1 3
10498 F 3.2 A 1.4 3.6 7.4 8.6 NP . ˉ N N 1 3
10499 F 3 A 1.5 3.7 7.5 8.7 NP . ˉ N N 1 3
10501 F 3 A 1.6 3.8 7.6 8.8 NP . ˉ N N 1 3
10503 F 3 A 1.7 3.9 7.7 8.9 NP . ˉ N N 1 3
10504 F 3 A 1.9 4.1 8.3 9.1 NP . ˉ N N 1 3
10506 F 3 A 2 4.2 8.4 9.2 NP . ˉ N N 1 3
10507 F 3.2 A 2.1 4.3 8.5 9.3 NP . ˉ N N 1 3
10511 F 3.2 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 3
10513 F 3.1 A 2.3 4.5 8.7 9.5 NP . ˉ L N 1 3
10518 F 3.2 A 1.3 3.5 7.3 8.5 NP . ˉ L N 1 3
10520 F 3.2 A 1.4 3.6 7.4 8.6 NP . ˉ L N 1 3
10521 F 3 A 1.5 3.7 7.5 8.7 NP . ˉ L N 1 3
10523 F 3.2 A 1.6 3.8 7.6 8.8 NP . ˉ L N 1 3
10524 F 3.1 A 1.7 3.9 7.7 8.9 NP . ˉ L N 1 3
10530 F 3.1 A 1.9 4.1 8.3 9.1 NP . ˉ L N 1 3
10533 F 3.2 A 2 4.2 8.4 9.2 NP . ˉ L N 1 3
10536 F 3.2 A 2.1 4.3 8.5 9.3 NP . ˉ L N 1 3
10538 F 3 A 2.2 4.4 8.6 9.4 NP . ˉ L N 1 3
